Sorry!! The article you are trying to read is not available now.
Thank you very much;
you're only a step away from
downloading your reports.

Pfizer Dealt an Alzheimer's Blow


The pharma giant and Medivation had high hopes for Dimebon but testing proved otherwise.

It should have come as no surprise that a Russian allergy medication was not an effective treatment for Alzheimer's disease, but shareholders and believers-in-miracles are all a bit disappointed by today's news that Pfizer (PFE) and Medivation (MDVN) didn't find the magic bullet for the debilitating disease.

The companies announced the preliminary results from their Connection study, a late-stage clinical trial testing the effectiveness of Dimebon in the treatment of patients with mild-to-moderate Alzheimer's, that showed the drug did not meet primary or secondary endpoints. The announcement sent shares of Medivation down almost 70% in pre-market trading, with the stock continuing to linger around $13 per share for the remainder of the trading day.

"The results from the Connection study are unexpected, and we are disappointed for the Alzheimer's community," said Medivation's chief executive Dr. David Hung. "We are working with our colleagues at Pfizer to better understand the Connection data and we plan to present these data at an upcoming medical meeting."

Dimebon has an interesting background; the 20-year-old drug was used as an antihistamine in Russia until it was replaced by other, newer drugs that entered the market. It is no longer marketed anywhere, but researchers continued to do studies on the drug in rodents and found that it blocked certain neurological pathways suspected to be related to neurodegenerative diseases like Alzheimer's and Huntington's disease. Pfizer and Medivation are still conducting four other clinical trials in humans to determine the safety and effectiveness of the drug in patients with both diseases.

"We are evaluating the Connection data with Medivation. After that review, Pfizer will be in a position to determine appropriate next steps regarding the Dimebon program," said Dr. Briggs W. Morrison, senior vice president, clinical development, Primary Care Business Unit at Pfizer.

While this is clearly a huge hit to a small company like Medivation, the implications for Pfizer could be just as detrimental. Leerink Swann analyst Seamus Fernandez called the results "disappointing" and said "it removes an upside opportunity from Pfizer's late-stage pipeline."

Dimebon's failure means that Pfizer won't have another late-stage drug to report on until the end of this year -- a long time for one of the world's largest pharmaceutical companies. It also means that Pfizer will miss out in plenty of revenues -- Fernandez had predicted that the drug would be pulling in $425 million worldwide by 2016.

The negative results of the Connection study have come as a shock to many, but others were already skeptical. The earlier studies that pointed to the drug's effectiveness in the treatment of Alzheimer's were done largely in Russia with small groups of patients. Many shareholders and analysts were concerned that the results of these studies could not be taken at face value due to the size of the study or the fact that Alzheimer's drugs aren't used very widely in the Russian population.

Pfizer is currently developing eight other drugs for the treatment of Alzheimer's disease, but analysts and shareholders won't know what effect the Dimebon results will have on the rest of the pipeline until after more data is released. It is likely that some of Pfizer's other drugs won't be successful either.

The treatments currently on the market can slow the progression of the disease, but not cure it, and drugs aren't an option for all patients. Pfizer and its partner Eisai market Aricept, the most widely prescribed medication for people in all phases of the disease who exhibiting signs of cognitive impairment.

Buzz & Banter: Where 30 professional traders share trading ideas and insights in real-time. Take a FREE 14 day trial to begin getting inside insights not available anywhere else. Learn more.
< Previous
  • 1
Next >
No positions in stocks mentioned.

The information on this website solely reflects the analysis of or opinion about the performance of securities and financial markets by the writers whose articles appear on the site. The views expressed by the writers are not necessarily the views of Minyanville Media, Inc. or members of its management. Nothing contained on the website is intended to constitute a recommendation or advice addressed to an individual investor or category of investors to purchase, sell or hold any security, or to take any action with respect to the prospective movement of the securities markets or to solicit the purchase or sale of any security. Any investment decisions must be made by the reader either individually or in consultation with his or her investment professional. Minyanville writers and staff may trade or hold positions in securities that are discussed in articles appearing on the website. Writers of articles are required to disclose whether they have a position in any stock or fund discussed in an article, but are not permitted to disclose the size or direction of the position. Nothing on this website is intended to solicit business of any kind for a writer's business or fund. Minyanville management and staff as well as contributing writers will not respond to emails or other communications requesting investment advice.

Copyright 2011 Minyanville Media, Inc. All Rights Reserved.

Featured Videos